Meet Eligo, the Startup which Raised €2M to Redefine Antibiotics using CRISPR

09/07/2015 - 6 minutes

Antibiotic resistance is a public health problem worldwide. According to WHO, by 2050, over 10 million people will die every year. Microbiomics is a fast evolving field which could play an important role in fighting these resistant bacteria. And CRISPR is literally seen as the biggest Biotech discovery of this century. So, here’s a crazy thought… what would happen if you were to mix Antibiotics, Microbiome and CRISPR together?

Xavier Duportet is a young entrepreneur, co-founder and CEO of Paris-based Eligo Bioscience, trying to use CRIPSR and all its potential to cure microbiome diseases. Today, the one-year old company proudly announced that it raised €2M from French VC Seventure Partners, which recently opened the first fund dedicated to microbiomics.

I had the pleasure of meeting Xavier several times before, and every time I felt impressed with him. He is a brilliant scientist who did his PhD at MIT. Today, he organizes the Hello Tomorrow Challenge and is always very enthusiastic.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member